Sanaria is a pioneering private biotech developing a novel class of malaria vaccines based on live, attenuated sporozoites (PfSPZ). The company has advanced multiple candidates into clinical development, with its PfSPZ-LARC2 vaccine representing a potential single-dose, transformative solution. Sanaria operates through a global collaborative model via the International PfSPZ Consortium (i-PfSPZ-C), positioning itself at the forefront of the fight for malaria elimination, targeting both individual protection and community-wide transmission interruption.
Infectious Disease
Technology Platform
Utilizes whole, live-attenuated *Plasmodium falciparum* sporozoites (PfSPZ), either radiation-attenuated (RAS) or genetically attenuated (GAP), as the immunogen to induce protective immunity against malaria.
Funding History
2
Total raised:$22.7M
Grant$9.3MNational Institute of Allergy and Infectious Diseases
Grant$13.4MNational Institute of Allergy and Infectious Diseases
Opportunities
The urgent global need for more effective malaria vaccines, especially in Africa, presents a massive market.
The potential for a single-dose, highly protective vaccine (PfSPZ-LARC2) could offer a significant advantage over current multi-dose options and be transformative for eradication campaigns.
Success could also open markets for travelers and military personnel.
Risk Factors
The complex, intravenous administration of most candidates is a major logistical barrier for mass vaccination.
Scaling up the unique and delicate manufacturing process for live sporozoites is costly and challenging.
The company faces competition from already-approved, easier-to-administer vaccines and remains pre-revenue, reliant on external funding.
Competitive Landscape
Sanaria competes with GSK (Mosquirix) and Serum Institute of India/University of Oxford (R21), which have approved, moderately effective vaccines administered intramuscularly. Sanaria's key competitive hypothesis is that its platform can achieve significantly higher and more durable protection, potentially with a single dose, justifying its more complex delivery system.
